Ultragenyx announced accelerated approval of GENGLYCOS on August 19, four days before the DTX401 target. The label accepts reduction in daily cornstarch intake as the basis for treating patients eight years and older with glycogen storage disease type Ia. Continued approval may depend on verification of clinical benefit through a post-marketing program.
That distinction matters. FDA accepted the measured reduction in treatment burden. It did not declare the longer-term clinical-benefit question closed.
Capricor’s August 22 target has now passed. As of Sunday, August 23, Capricor has not publicly announced an FDA action, confirmed submission of the planned amendment, or disclosed a formal extension and replacement date. The correct status is pending—not approval, rejection or extension by inference.
The next clean clock is Jazz on August 25, followed by Gilead on August 27. Three hard September dates absent from the raw file also enter the board: Ultragenyx’s UX111 on September 19, Merck’s WINREVAIR label update on September 21 and Ionis’ zilganersen on September 22.
| Published date | Sponsor / ticker | Event | Current status | Main risk | PoA |
| Sat Aug 22* | CAPR | deramiocel / DMD | No public FDA action or replacement date as of Sunday | Evidence adequacy / indication shift / BIMO inspection and data integrity | 10% |
Capricor previously said it planned to submit an amendment centered on upper-limb function and expected FDA to extend the review after receiving it. As of Sunday, the company had not publicly confirmed the amendment, a formal extension or a new target date. FDA’s public briefing document disclosed BIMO inspection assignments for the sponsor and one clinical site, plus preliminary audit-trail findings involving the approved blinding plan and transfer of statistical work in-house. Capricor has also said potential approval would make it eligible for a Rare Pediatric Disease Priority Review Voucher.
| Date | Sponsor / ticker | Event | Setup class | Main risk | PoA |
| Tue Aug 25 | JAZZ | Ziihera combinations / first-line HER2+ GEA | Priority Review sBLA / RTOR | Regimen and label scope | 83% |
| Thu Aug 27 | GILD | bictegravir/lenacapavir / suppressed HIV | Priority Review NDA | Resistance history / population and label scope | 89% |
| Sun Aug 30 | PharmaEssentia (TWSE-listed) | BESREMi / essential thrombocythemia | Standard Review sBLA | Population / safety / execution | 87% |
| Thu Sep 3 | Advicenne (Euronext-listed) | Sibnayal / distal renal tubular acidosis | 505(b)(2) NDA | U.S. bridging / CMC / label | 78% |
| Fri Sep 11 | Telix (ASX/Nasdaq-listed) | TLX101-Px / Pixclara / glioma PET imaging | Resubmitted 505(b)(2) NDA / Fast Track / Orphan Drug | Diagnostic evidence / resubmission execution | 75% |
| Sat Sep 19 | RARE | UX111 / Sanfilippo syndrome type A | Resubmitted BLA / accelerated-approval request / RMAT | CMC and inspections / natural-history and biomarker package | 74% |
| Mon Sep 21 | MRK | WINREVAIR / recently diagnosed PAH label update | sBLA / positive Phase 3 HYPERION | Label wording / execution | 96% |
| Tue Sep 22 | IONS | zilganersen / Alexander disease | Priority Review NDA / Breakthrough Therapy | Small-trial endpoint robustness / label / execution | 84% |
Board dates reflect current company and FDA disclosures. Private and non-U.S.-listed sponsors are identified by sponsor name. PoAs are PDUFA Pulse editorial estimates rounded to whole numbers.
| JAZZ$JAZZ · Ziihera combinations | Tuesday, August 25 83% |
Jazz is seeking first-line approval of Ziihera with chemotherapy, with or without tislelizumab, in HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
The 914-patient Phase 3 HERIZON-GEA-01 trial produced a strong efficacy package. Both Ziihera-containing regimens improved median progression-free survival to 12.4 months from 8.1 months with trastuzumab plus chemotherapy, with hazard ratios of 0.63–0.65. The triplet also improved median overall survival to 26.4 months from 19.2 months, HR 0.72.
The main question is not whether the trial was positive. It is how much of the package FDA puts into the label. The triplet has mature positive overall-survival evidence. At the first interim analysis, the Ziihera-plus-chemotherapy doublet produced median overall survival of 24.4 months versus 19.2 months, HR 0.80, p=0.06—favorable, but not statistically significant. Jazz now expects the second interim doublet OS analysis in the third quarter of 2026 and had not disclosed it as of Sunday. FDA must also decide how broadly to write HER2 and PD-L1 eligibility and whether both regimens emerge with equivalent prominence.
| GILD$GILD · bictegravir/lenacapavir | Thursday, August 27 89% |
Gilead is seeking approval for bictegravir 75 mg plus lenacapavir 50 mg as a once-daily, two-drug single-tablet regimen for adults with HIV who are already virologically suppressed.
Both Phase 3 switch comparisons met noninferiority. In ARTISTRY-1, 0.8% of patients switched from complex regimens to BIC/LEN had HIV-1 RNA of at least 50 copies/mL at Week 48 versus 1.1% who remained on their baseline regimens, with no treatment-emergent resistance. In double-blind ARTISTRY-2, the corresponding rates were 1.3% with BIC/LEN and 1.0% with Biktarvy.
The disclosed efficacy case is straightforward. The residual question is who FDA permits to switch. ARTISTRY-1 included patients on complex regimens, often because resistance, intolerance, contraindications or drug interactions limited simpler options. That makes resistance-history language central to the commercial value of the label.
Last week, the DTX401 question was whether FDA would accept reduced cornstarch burden as meaningful enough to support approval.
The answer was yes—but through accelerated approval.
That is not a semantic footnote. FDA approved the product on the measured reduction in daily cornstarch intake while requiring a post-marketing program to verify clinical benefit. The label therefore validates the endpoint and preserves the uncertainty at the same time.
The analytical mistake is to treat every approval as the same evidentiary conclusion. Full approval, accelerated approval and a narrow label can all produce a positive headline while answering different questions about what FDA believes has been established.
The operational rule: after a positive binary, read the pathway, indication, limitations of use and post-marketing requirements before declaring the thesis confirmed.
| CAPR | Did the amended upper-limb case remain insufficient, or did BIMO, CMC or another application issue remain open? |
| JAZZ | Did FDA approve only one regimen, narrow the population, or encounter an undisclosed CMC or inspection issue? |
| GILD | Did resistance history, population definition, regimen composition or application execution prevent approval? |
| PharmaEssentia (TWSE-listed) | Did FDA narrow the ET population, require additional safety controls or find an execution issue in the sBLA? |
| Advicenne (Euronext-listed) | Did the European-data bridge, 505(b)(2) basis, CMC package or proposed U.S. label fail to close? |
| Telix (ASX/Nasdaq-listed) | Did the resubmission fail to resolve FDA’s diagnostic-evidence concerns, or did label or manufacturing remain open? |
| RARE / UX111 | Did CMC or inspection remediation remain incomplete, or did FDA reject the natural-history and biomarker package for accelerated approval? |
| MRK | Did an unexpected label, safety or application-execution issue block the HYPERION update? |
| IONS | Did FDA find the small pivotal study, gait endpoint or narrowly significant result insufficiently robust, or did execution intervene? |
The board has moved from endpoint anticipation to endpoint interpretation.
Resolved this cycle: RARE / GENGLYCOS, approved August 19 under accelerated approval.
Pending after its published date: CAPR / deramiocel.
Live: JAZZ → GILD → PharmaEssentia → Advicenne → Telix → RARE / UX111 → MRK → IONS.
Next hard clock: JAZZ on August 25.
Highest-drama name: CAPR. The date has passed, but neither the FDA outcome nor the amendment-and-extension mechanics are public.
Corporate overlay: On August 21, Kaos Capital, describing itself as a significant and growing shareholder, called for a board meeting, two independent-director nominees, a capital-preservation plan and a board-led M&A and Strategic Alternatives Committee. That pressure does not change the FDA evidence case, but it raises the corporate stakes around the unresolved decision.
Cleanest setup: MRK. WINREVAIR is already approved, and HYPERION reduced clinical-worsening risk by 76% in the population covered by the proposed label update.
Most consequential near-term label read: JAZZ. The binary looks favorable; the doublet-versus-triplet positioning is the real decision.
That is the queue.
Informational only · Not investment advice · Biotech carries risk of total loss.